Innovation for Life

Developing Innovative drugs, Biosimilars, Platforms, and Diagnostic technologies to improve lives.

Advancing Antibody Science

Advancing antibody drugs and biosimilars to address unmet medical needs.

Creating Value for a Healthier Life

Improving patient access through cost-effective, high-quality biosimilars.

PRESTIGE BIOPHARMA

PRESTIGE BIOPHARMA IDC

PRESTIGE BIOLOGICS

7

Beyond technological discovery, expanding access to care for patients around the world

Innovative Drug

Development of First-in-Class therapeutics for unmet diseases

Biosimilar

Prominent Biosimilars pipelines for accelerating market access

Platform Technology

A drug delivery platform that enhances treatment convenience

Diagnostics

Diagnostics for Pancreatic cancer by detecting PAUF

Prestige News

Total 76
Number Thumbnail Title Author Date Votes Views
76 Prestige Biopharma Receives Brazilian Marketing Authorization for Herceptin Biosimilar Tuznue
김** | 2026.09.28 | Votes 0 | Views 121
김** 2026.09.28 0 121
75 Prestige Biopharma’s Tuznue Receives Marketing Authorization in Trinidad and Tobago
김** | 2026.09.18 | Votes 0 | Views 544
김** 2026.09.18 0 544
74 Prestige Biopharma IDC Obtains ISO 14001 and ISO 45001 Certifications
김** | 2026.09.17 | Votes 0 | Views 354
김** 2026.09.17 0 354
73 Prestige Biopharma Successfully Concludes ‘Prestige Symposium’ on Aging
김** | 2026.09.09 | Votes 0 | Views 943
김** 2026.09.09 0 943
72 Prestige Biopharma IDC CEO Ko Sang-seok Purchases Company Shares on the Open Market
김** | 2026.09.03 | Votes 0 | Views 1136
김** 2026.09.03 0 1136
71 Prestige Biopharma’s Tuznue Secures Brazilian GMP Certification, Supporting Latin American Approval Process
김** | 2026.08.25 | Votes 0 | Views 1834
김** 2026.08.25 0 1834
70 Prestige Biopharma Files Patent Application for TASA™, a Blood-Based Pancreatic Cancer Diagnostic Platform
김** | 2026.08.12 | Votes 0 | Views 1870
김** 2026.08.12 0 1870
69 Prestige Biopharma Positions PBP1710 as Its Next-Generation Growth Driver
김** | 2026.08.11 | Votes 0 | Views 2365
김** 2026.08.11 0 2365
68 Prestige Biopharma CEO Soyeon Park Purchases Approximately 70,000 Additional Shares, Bringing Total Purchases to 161,765 Shares
김** | 2026.08.04 | Votes 0 | Views 2295
김** 2026.08.04 0 2295
67 Prestige Biopharma IDC Publishes Preclinical Efficacy Results of IDC007 in International Academic Journal
김** | 2026.07.16 | Votes 0 | Views 3400
김** 2026.07.16 0 3400

Read Prestige news >>

FY2026
Shareholder Letter
FY2026
Shareholder Letter